Centre reserves 30 crore COVID vaccine doses of Biological-E
   Date :04-Jun-2021

30 crore COVID vaccine_1&
 
 
NEW DELHI :
 
The COVID-19 vaccine of Biological-E is currently undergoing phase-3 clinical trial after showing promising results in phase 1 and 2 trials 
 
THE Union Health Ministry has finalised arrangements with Hyderabad-based vaccine manufacturer Biological-E to reserve 30 crore COVID-19 vaccine doses for which it will be making an advance payment of Rs 1500 crore. These vaccine doses will be manufactured and stockpiled by Biological-E from August to December this year, a Ministry statement said on Thursday. The COVID-19 vaccine of Biological-E is currently undergoing phase-3 clinical trial after showing promising results in phase 1 and 2 trials.
 
The vaccine being developed by Biological-E is a RBD protein sub-unit vaccine and is likely to be available in the next few months. The proposal of Biological-E was examined and recommended for approval after due diligence by the National Expert Group on Vaccine Administration for COVID-19 (NEGVAC), the statement said. The arrangement with Biological-E is part of the wider endeavour of the Centre to encourage indigenous vaccine manufacturers by providing them support in research and development and also financial support, it said.